Male breast cancer: common biomarkers, clinicopathology, and outcomes in the west of Iran.

IF 2.1 Q3 ONCOLOGY

Journal of the Egyptian National Cancer Institute Pub Date : 2025-05-07 DOI:10.1186/s43046-025-00294-y

Ali Azizi, Nasrin Mansouri, Bayan Faridi, Mazaher Ramezani

{"title":"Male breast cancer: common biomarkers, clinicopathology, and outcomes in the west of Iran.","authors":"Ali Azizi, Nasrin Mansouri, Bayan Faridi, Mazaher Ramezani","doi":"10.1186/s43046-025-00294-y","DOIUrl":null,"url":null,"abstract":"Background: Male breast cancer is a rare disease that accounts for less than 1% of all cancers in men and less than 1% of all diagnosed breast cancers. We retrospectively evaluated clinicopathologic features, treatment options, and overall survival in male breast cancer cases over 10 years (2012-2021).Methods: In this descriptive-cross-sectional study, the men with a breast cancer patient information based on demographic characteristics, type of surgery performed, pathological characteristics of samples (including the type of tumor involving lymph nodes and its grade), distant metastasis, immunohistochemical markers as well as family history of cancer, number of chemotherapy and radiotherapy sessions, use of anabolic drugs, and patient survival after surgery were recorded in the designed checklist.Results: The results showed that the mean age of men with breast cancer was 56.14 ± 14.59. Invasive ductal carcinoma was diagnosed in 86.3% of patients. In addition, metastasis occurred in 23.5% of patients, and most metastases occurred in the liver and then in the bone marrow, respectively. The highest frequency was related to stage IIB, with a frequency of 29.4%. The overall survival rate of 1, 3, and 5 years for 51 cases was 96%, 91%, and 65%, respectively, with an average survival period of 96 months. There was a significant relationship between age, metastasis, and disease stage with the survival status of patients (P = 0.03).Conclusions: In the present study, old age, higher stage, and metastasis in male breast cancer were associated with unfavorable survival.","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"37 1","pages":"35"},"PeriodicalIF":2.1000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Egyptian National Cancer Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43046-025-00294-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Male breast cancer is a rare disease that accounts for less than 1% of all cancers in men and less than 1% of all diagnosed breast cancers. We retrospectively evaluated clinicopathologic features, treatment options, and overall survival in male breast cancer cases over 10 years (2012-2021).

Methods: In this descriptive-cross-sectional study, the men with a breast cancer patient information based on demographic characteristics, type of surgery performed, pathological characteristics of samples (including the type of tumor involving lymph nodes and its grade), distant metastasis, immunohistochemical markers as well as family history of cancer, number of chemotherapy and radiotherapy sessions, use of anabolic drugs, and patient survival after surgery were recorded in the designed checklist.

Results: The results showed that the mean age of men with breast cancer was 56.14 ± 14.59. Invasive ductal carcinoma was diagnosed in 86.3% of patients. In addition, metastasis occurred in 23.5% of patients, and most metastases occurred in the liver and then in the bone marrow, respectively. The highest frequency was related to stage IIB, with a frequency of 29.4%. The overall survival rate of 1, 3, and 5 years for 51 cases was 96%, 91%, and 65%, respectively, with an average survival period of 96 months. There was a significant relationship between age, metastasis, and disease stage with the survival status of patients (P = 0.03).

Conclusions: In the present study, old age, higher stage, and metastasis in male breast cancer were associated with unfavorable survival.

查看原文本刊更多论文

伊朗西部男性乳腺癌：常见的生物标志物、临床病理和预后。

背景：男性乳腺癌是一种罕见的疾病，占男性所有癌症的不到1%，占所有诊断乳腺癌的不到1%。我们回顾性评估了10年（2012-2021年）男性乳腺癌病例的临床病理特征、治疗方案和总生存率。方法:在这项描述性横断面研究中，在设计的检查表中记录了男性乳腺癌患者的人口统计学特征、手术类型、样本病理特征（包括肿瘤累及淋巴结的类型及其分级）、远处转移、免疫组织化学标志物以及癌症家族史、化疗和放疗次数、合成代谢药物的使用以及术后患者生存等信息。结果：男性乳腺癌患者平均年龄为56.14±14.59岁。86.3%的患者诊断为浸润性导管癌。此外，23.5%的患者发生转移，大多数转移分别发生在肝脏和骨髓。发病率最高的是IIB期，为29.4%。51例患者1年、3年和5年的总生存率分别为96%、91%和65%，平均生存期为96个月。年龄、转移、疾病分期与患者生存状况有显著相关性（P = 0.03）。结论：在本研究中，男性乳腺癌年龄大、分期高、转移与生存不利相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the Egyptian National Cancer Institute ONCOLOGY-

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

11 weeks

期刊介绍： As the official publication of the National Cancer Institute, Cairo University, the Journal of the Egyptian National Cancer Institute (JENCI) is an open access peer-reviewed journal that publishes on the latest innovations in oncology and thereby, providing academics and clinicians a leading research platform. JENCI welcomes submissions pertaining to all fields of basic, applied and clinical cancer research. Main topics of interest include: local and systemic anticancer therapy (with specific interest on applied cancer research from developing countries); experimental oncology; early cancer detection; randomized trials (including negatives ones); and key emerging fields of personalized medicine, such as molecular pathology, bioinformatics, and biotechnologies.